Clinical Trial

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously received taxane-based chemotherapy with or without immunotherapy and an antibody-drug conjugate with a topoisomerase inhibitor payload
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-22.
Trial Details
NCT Number NCT07556848
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Locally Advanced or Metastatic Triple-negative Breast Cancer
Enrollment 356 participants
Start Date 2026-05
Primary Completion 2027-12 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-30